| 发明名称 | p62-ZZ chemical inhibitor | ||
| 摘要 | A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound. | ||
| 申请公布号 | US9580382(B2) | 申请公布日期 | 2017.02.28 |
| 申请号 | US201214237494 | 申请日期 | 2012.08.08 |
| 申请人 | ID4Pharma, LLC | 发明人 | Xie Xiang-Qun;Roodman Garson David;Myint Kyaw-Zeyar;Kurihara Noriyoshi |
| 分类号 | C07D475/08;C07C229/36;C07D309/40;C07C211/50;C07C317/34;C07C217/58;C07C217/76;C07C219/06;C07D241/44;C07C229/14;C07D487/04;C07C235/48;C07C251/76;A61K31/137;A61K31/351;A61K31/495;A61K31/519;A61K31/15;A61K31/498;A61K45/06;C07C249/16;C07D309/32;C12N5/09;A61K31/216 | 主分类号 | C07D475/08 |
| 代理机构 | DLA Piper LLP (US) | 代理人 | DLA Piper LLP (US) |
| 主权项 | 1. A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of Formula I: wherein Ar is an arylene; R1 has a structure of: wherein W is an alkanediyl, X is —NR5—, R5 is H, and Y is a hydroxyalkyl; each R2 is the same or different and has a structure of: wherein Z is —NR6, R6 is H, Z1 is (—CH2—), Cy is a 6-membered aryl ring, and each R4 is the same halogen, and wherein c is 1, and a is 2. | ||
| 地址 | Pittsburgh PA US | ||